reports
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as t...
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placeboAFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring ...
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé au...
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par une étude de phase 3 démontrant que Dupixent a réduit de manière significative les signes et symptômes nasaux ainsi que le recours aux corticostéroïdes systémiques ou à la chirurgie par rapport au placeboL’AFRS e...
- James Ratzer
- Julian Dobrovolschi
- Research Department
TELEFÓNICA: 4Q’25 RESULTS (ANÁLISIS BANCO SABADELL)
4Q'25 vs. 4Q'24 Results Sales: € 9.174 Bn (-14.3% vs. -15.5% BS(e) and -15.0% consensus); EBITDA: € 3.198 Bn (+88.0% vs. +82.8% BS(e) and +85.3% consensus); EBIT: € -1.775 Bn (€ -511.0 M in FY2024 vs. € -1.300 Bn BS(e) and € -1.203 Bn consensus); Net Profit: € -3.239 Bn (€ -1.003 Bn in FY2024 vs. € -1.201 Bn BS(e) and € -1.425 Bn consensus); FY2025 vs. FY2024 Results Sales: € 36.145 Bn (-12.1% vs. -12.4% BS(e) and -12.3% consensus); EBITDA: € 12.164 Bn (+9.9% vs. +9.1% BS(e) and +9.5% consensus)...
- Julian Dobrovolschi
- Alvaro del Pozo
TELEFÓNICA: RDOS. 4T’25 (ANÁLISIS BANCO SABADELL)
Rdos. 4T'25 vs 4T'24: Ventas: 9.174 M euros (-14,3% vs -15,5% BS(e) y -15,0% consenso); EBITDA: 3.198 M euros (+88,0% vs +82,8% BS(e) y +85,3% consenso); EBIT: -1.775,0 M euros (-511,0 M euros en 2024 vs -1.300,0 M euros BS(e) y -1.203,0 M euros consenso); BDI: -3.239,0 M euros (-1.003,0 M euros en 2024 vs -1.201,0 M euros BS(e) y -1.425,0 M euros consenso). Rdos. 2025 vs 2024: Ventas: 36.145 M euros (-12,1% vs -12,4% BS(e) y -12,3% consenso); EBITDA: 12.164 M euros (+9,9% vs +9,1% BS(e) y +9,5%...
- Research Department
INFORME DIARIO 24 FEBRERO + RDOS. ESPAÑA Y EUROPA. IDEAS DESTACADAS Y ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAF, ENCE, ENDESA, METROVACESA, TELEFÓNICA. EUROPA: N/A. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El Ibex se desmarca en positivo Los índices europeos mostraron una reacción mixta a las nuevas amenazas proteccionistas de Trump (mejor p...
- Research Department
IBERIAN DAILY 24 FEBRUARY + 4Q’25 RESULTS. HIGHLIGHTS AND REST OF PREV...
NEWS SUMMARY: CAF, ENCE, ENDESA, METROVACESA, TELEFÓNICA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. IBEX the one positive note European stock markets showed a mixed reaction to Trump’s new protectionist measures (the periphery outperformed core countries), while companies exposed to the disruption from AI continu...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
Coffee, Croissants & Credit/Orange, VodafoneZiggo, Virgin Media O2, Te...
Orange reports solid FY25 results / Liberty Global announced the intention to list VodafoneZiggo in 2027 / Liberty Global, Telefonica and InfraVie to acquire Substantial Group / Equinix upgrade by Moody's to Baa1 / Covivio FY25 results: portfolio rotation continues to deliver
Press release: Filing of the 2025 U.S. Form 20-F and French “Document ...
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company’s ...
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 20...
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 17 février 2026. Sanofi annonce avoir déposé son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France et son « Form 20-F » auprès de la « Securities and Exchange Commission » (SEC) aux Etats-Unis. Le rapport du Conseil d’administration ...
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data d...
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potent...
Communiqué de presse : Les données de phase IIb de l’étude d’entretien...
Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Dans l’étude de phase IIb RELIEVE UCCD LTE, le duvakitug a montré une efficacité robuste et durable pendant 44 semaines supplémentaires chez les patients atteints de CU et de MC qui ava...
- Maxime Kogge
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
RI PERNOD RICARD SA
RCO REMY COINTREAU SA
FHZN FLUGHAFEN ZURICH AG
ISP INTESA SANPAOLO S.P.A.
UCG UNICREDIT S.P.A.
NN NN GROUP N.V.
CLNX CELLNEX TELECOM S.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
CCEP COCA-COLA EUROPEAN PARTNERS PLC
IHG INTERCONTINENTAL HOTELS GROUP PLC
CPR DAVIDE CAMPARI-MILANO N.V.
- Maxime Kogge
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
RI PERNOD RICARD SA
RCO REMY COINTREAU SA
FHZN FLUGHAFEN ZURICH AG
ISP INTESA SANPAOLO S.P.A.
UCG UNICREDIT S.P.A.
NN NN GROUP N.V.
CLNX CELLNEX TELECOM S.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
IHG INTERCONTINENTAL HOTELS GROUP PLC
CPR DAVIDE CAMPARI-MILANO N.V.
- Ana Arjona-Martinez
Press Release: Beyfortus study published in The Lancet Infectious Dise...
Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season Data published in The Lancet Infectious Diseases and to be presented at RSVVW ’26 conference in Rom...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.